DOC1021

Natera Partners with Diakonos Oncology to Evaluate Signatera in Refractory Melanoma Trial

AUSTIN, Texas | May 2026 Natera, Inc. announced a new collaboration with Diakonos Oncology Corp. to utilize its personalized...

By cGxPwire Editor
May 30, 2026

Bio-Pharma

Diakonos Gains FDA Fast Track for DOC1021 Melanoma

HOUSTON, May 6, 2026 Diakonos Oncology Corp., a clinical-stage biotechnology company focused on next-generation cancer immunotherapies, has announced that...

By cGxPwire Editor
May 7, 2026

We work Hard to get you posted with latest updates

Unwrap our new Directory

DOC1021

Natera Partners with Diakonos Oncology to Evaluate Signatera in Refractory Melanoma Trial

Diakonos Gains FDA Fast Track for DOC1021 Melanoma